EGFR and hepatocellular carcinoma: It was hypothesized that EGFR inhibition, via erlotinib, would enhance tumor response due to both the implicated roles of the EGFR pathway in the pathogenesis of HCC and that of EGFR activation interfering with HCC response to sorafenib [24,25].